90299-04-0

Usage

Uses

Used in Organic Synthesis:
(1-METHYL-1-(NAPHTH-2-YL)ETHYL)AMINE is used as a building block in organic synthesis for the preparation of various drug molecules and bioactive compounds. Its unique structure allows it to be a versatile component in the creation of complex organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, (1-METHYL-1-(NAPHTH-2-YL)ETHYL)AMINE is utilized as a key intermediate for the synthesis of potential drug candidates. Its ability to be incorporated into a wide range of molecules makes it valuable in the discovery and development of new therapeutic agents.
Used as a Reagent in Chemical Reactions:
(1-METHYL-1-(NAPHTH-2-YL)ETHYL)AMINE also serves as a reagent in chemical reactions, where it can introduce the (1-methyl-1-(naphth-2-yl)ethyl)amine functionality into other molecules. This capability is crucial for the modification and enhancement of the properties of existing compounds, leading to improved pharmaceutical and chemical applications.

Upstream product

• 179097-01-9 2-(1-Azido-1-methyl-ethyl)-naphthalene 
• 2243-82-5 2-naphthamide 
• 94616-84-9 dichloromethylcerium 
• 100820-31-3 ethyl 2-(2-<3,4-dihydronaphthalenyl>)-2-methylpropanoate 
• 613-46-7 2-naphthalenecarbonitrile 
• 75-16-1 methylmagnesium bromide 
• 917-54-4 methyllithium 
• 2459-25-8 methyl naphthalene-2-carboxylate 
• 93-08-3 methyl 2-naphthyl ketone 
• 20351-54-6 2-(2-hydroxy-2-methylethyl)naphthalene 
• 605671-97-4 2-(3,4-dihydro-2-naphthalenyl)-2-methylpropanoyl azide 
• 605671-98-5 2-(3,4-dihydro-2-naphthalenyl)-2-methylethyl isocyanate 
• 605671-93-0 2-(3,4-dihydro-2-naphthalenyl)-2-methylethylamine 
• 94041-94-8 2-<2-(2,2-Dihydronaphthalenyl)>-2-methylpropanoic acid 

Downstream Products

• 179096-85-6 N-(2-Hydroxy-ethyl)-2-methyl-N-(1-methyl-1-naphthalen-2-yl-ethyl)-benzamide 
• 1422208-58-9 C₂₃H₂₈N₂O*ClH 
• 1422207-64-4 C₃₇H₄₅N₃O₃ 
• 1422208-42-1 C₂₈H₃₆N₂O₃ 

Relevant academic research and scientific papers

Native Amine-Directed ortho -C-H Halogenation and Acetoxylation /Condensation of Benzylamines

Free or unfunctionalized benzylamines are well known to participate in C-H activation in the presence of palladium salts. Despite the ease with which these complexes can be activated, subsequent functionalization of the dimeric cyclometalates can be chall

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent

The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019–0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC50 = 40–>120 μM) towards Vero cells. Significant improvements in mouse liver microsomal stability and mouse pharmacokinetic profile were realized by introduction of an α α-dimethylbenzyl moiety. Among these compounds, JSF-4088 is highlighted due to its in vitro antitubercular potency (MIC = 0.019 μM) and Vero cell cytotoxicity (CC50 > 120 μM). The findings suggest a rationale for the continued evolution of this promising series of antitubercular small molecules.

Glucosylceramide synthase inhibitors

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

Rapid Ti(Oi-Pr)4 facilitated synthesis of α,α,α-trisubstituted primary amines by the addition of Grignard reagents to nitriles under microwave heating conditions

A series of carbinamines (α,α,α-trisubstituted amines) have been prepared in a simple and efficient one-pot procedure by the addition of Grignard reagents to a series of aliphatic, aromatic and heteroaromatic nitriles. The resulting magnesium imines are subsequently converted to the desired amine after treatment with Ti(Oi-Pr)4 and additional microwave heating. Key to this procedure is the use of microwave heating for both steps of the reaction protocol, which significantly improves both reaction yields and reduces reaction times. In general, the Grignard addition reaction is complete within 5-10 min at 100 °C followed by conversion with Ti(Oi-Pr)4 and additional microwave heating to give the target amines in good yields.

Novel photoreactions of 2-Aza-1,4-dienes in the triplet excited state and via radical-cation intermediates. 2-Aza-di-π-methane rearrangements yielding cyclopropylimines and N-vinylaziridines

Triplet-sensitized irradiation of 2-aza-1,4-dienes affords N-cyclopropylimines via 2-aza-di-π-methane (2-ADPM) rearrangement pathways. In the case of the pentaphenyl-substituted azadiene 1, irradiation leads to formation of cyclopropylimine 2 as well as N-vinylaziridine 3. The transformations represent the first examples of di-π-methane rearrangement reactions that yield three-membered heterocyclic products. SET-sensitized irradiation of 2-aza-1,4-dienes, by using 9,10-dicyanoanthracene (DCA) as an electron-acceptor sensitizer and biphenyl as cosensitizer, brings about regioselective formation of N-vinylaziridines. Under these conditions, azadiene 1 also affords cyclopropylimine 37, resulting from an aryl-di-π-methane rearrangement. This result demonstrates that di-π-methane reactions can also take place via radical-cation intermediates. In some instances, imine and olefin centered cation-radical intermediates, generated by SET-sensitized irradiation, undergo alternative reactions to produce isoquinoline and benzoazepine products.

Organocerium reactions of benzamides and thiobenzamides: A direct synthesis of tertiary carbinamines

A simple and efficient process has been developed for the direct conversion of benzamides and thiobenzamides into tertiary carbinamines. A synthesis of benzonitriles from simple benzamides and a thiobenzamide is also described.

Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design

A series of potent nonpeptide inhibitors of the HIV protease have been identified. Using the structure of compound 3 bound to the HIV protease, his tertiary amide inhibitor 9 was designed and prepared. Compound 9 was found to be about 17 times more potent than 3, and the structure of the protein- ligand complex of 9 revealed the inhibitor binds in an inverted binding mode relative to 3. Examination of the protein-ligand complex of 9 suggested several modifications in the P1 and P1' pockets. Through these modifications it was possible to improve the activity of the inhibitors another 100-fold, highlighting the utility of crystallographic feedback in inhibitor design. These compounds were found to have good antiviral activity in cell culture, were selective for the HIV protease, and were orally available in three animal models.